GROWTH TRAJECTORIES OF CHILDREN AND ADOLESCENTS WITH ADHD TREATED WITH DELAYED-RELEASE/EXTENDED-RELEASE METHYLPHENIDATE (JORNAY PM®): A PILOT STUDY OF REAL-WORLD DATA FROM A LARGE US CLAIMS DATABASE

Abstract

Stimulants are associated with a slowed growth rate in pediatric patients with ADHD. DR/ER-MPH (formerly HLD200; trade name: JORNAY PM®) is an evening-dosed, delayed-release, and extended-release methylphenidate released in the colon; it has no immediate-release component and provides a dose-dependent duration of effect for individuals with ADHD. Herein, we report real-world weight and height changes in patients newly prescribed DR/ER-MPH in its first year of availability vs patients treated with 2 established branded stimulants, osmotic release oral system (OROS) MPH (Concerta®) and lisdexamfetamine dimesylate (LDX; Vyvanse®).